Topic:
VC / M&A
Latest Headlines
Latest Headlines
GSK deal chief hunts for 'hidden gems' to feed drug giant's pipeline
GlaxoSmithKline ( $GSK ) descended upon the big J.P. Morgan meeting in solid numbers this week as the U.K. drug giant scouted for a variety of deals with other companies in the biopharma arena. And Dow
Merck jumps in the biotech VC game with $250M plan
Big Pharma is betting more big bucks on early-stage biotech. As drugmakers seek more external sources of new products to feed their rusty R&D pipelines, drug giant Merck ( $MRK ) has plans to pump
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based
Do VC groups love the Web more than biotech?
CNET's Jim Kerstetter takes a look at biotech's anemic performance  in the latest round of M&A deals and concludes
Rocky market puts freeze on biotech deal-making
Turmoil on the Street has created a bleak financial landscape for emerging biotech companies. Only four biotech and medical device firms backed by venture capital outfits went public in the first
Troubled Pfizer blueprints biotech venture effort
Up to now, Pfizer's use of investment funds has followed a few narrow channels: Diagnostics, software and drug technology outfits that promised to help in their drug commercialization efforts. But
Tobira garners $31M to advance HIV drugs
Up-start biotech Tobira Therapeutics, which is developing HIV/AIDS drugs, has raised $31 million in its first round of venture capital. Domain Associates and Frazier Healthcare Ventures led the round
SurModics paying up to $62M for Brookwood
The Southern Research Institute has sold Brookwood Pharmaceuticals to SurModics for $40 million up front and up to $22 million in milestones. Both SurModics and Brookwood specialize in
